Abstract 1147P
Background
MCC is a rare, aggressive cutaneous neoplasm. In September 2017, the European Commission approved avelumab (Ave) for the tx of metastatic MCC based on demonstrated meaningful survival benefit. This study sought to investigate tx patterns and OS of pts with aMCC (stage III/IV) in the National Cancer Registration Dataset (NCRD) in England.
Methods
This cohort included pts ≥18 years and newly diagnosed with stage III/IV MCC (ICD-O: C44, 8247 morphology) between January 2013 and December 2020 in the NCRD in England and followed up until May 2022. Summary and descriptive statistics were calculated for categorical and continuous variables. The Kaplan-Meier method was used to estimate median OS from diagnosis date (overall) and OS from initiation of 1L tx stratified by regimens received and by stage at baseline.
Results
A total of 667 pts with aMCC were included. Mean age (SD) was 77.4 years (10.3), most pts were male (61.0%), and 14.1% were immunocompromised. At diagnosis, 66.3% and 33.7% had stage III and IV disease, respectively. The mean (SD) baseline modified Deyo-Charlson Comorbidity Index was 4.0 (1.8). Overall, 478 pts (71.7%) died during follow-up; median OS from diagnosis was 18.4 months (95% CI, 15.6-20.9). In total, 199 pts (29.8%) received 1L tx (39.2% Ave, 60.8% non-Ave). When stratified by stage, 26.9% of stage III pts received systemic tx (39.5% Ave, 60.5% non-Ave); the corresponding numbers for stage IV pts were 35.6% (38.7% Ave, 61.3% non-Ave). OS from 1L initiation is presented in the table. Table: 1147P
OS from 1L initiation | Stage III | Stage IV | ||
Ave | Non-Ave | Ave | Non-Ave | |
n | 47 | 72 | 31 | 49 |
Deaths during follow-up, n (%) | 20 (42.6) | 54 (75.0) | 16 (51.6) | 40 (81.6) |
Median OS months (95% CI) | 37.8 (12.9-NE) | 13.0 (8.3-19.6) | 19.9 (5.0-NE) | 7.2 (5.9-9.1) |
12-months survival rate, % (95% CI) | 67 (51-79) | 52 (40-63) | 55 (36-70) | 31 (18-44) |
18-months survival rate, % (95% CI) | 56 (39-69) | 41 (29-52) | 52 (33-67) | 24 (14-37) |
24-months survival rate, % (95% CI) | 56 (39-69) | 35 (24-46) | 48 (29-64) | NE |
NE, not estimable.*Non-Ave includes 95.5% chemotherapy and 4.5% other treatment.
Conclusions
This nationwide real-world study of pts with aMCC demonstrates the effectiveness of Ave with considerably prolonged survival in pts with both stage III and stage IV disease. The study findings validate results from the JAVELIN Merkel 200 clinical trial and other observational studies.
Clinical trial identification
Editorial acknowledgement
Editorial support was provided by Eleanor Bishop on behalf of Clinical Thinking and was funded by Merck and Pfizer.
Legal entity responsible for the study
The authors.
Funding
This study was sponsored by Merck (CrossRef Funder ID: 10.13039/100009945), as part of an alliance between Merck and Pfizer.
Disclosure
C. Knott: Financial Interests, Personal, Full or part-time Employment: Health Data Insight CIC; NHS England. S. Mahmoudpour, M. Kearney: Financial Interests, Personal, Full or part-time Employment: Merck. E. Boutmy: Financial Interests, Personal, Full or part-time Employment: Merck; Financial Interests, Personal, Stocks/Shares: Merck. P. Verpillat: Financial Interests, Personal, Full or part-time Employment, at the time of the study: Merck.
Resources from the same session
1171P - Evaluation of the transcriptomic presence of tumor associated antigens (TAAs) from antibody drug conjugates (ADCs) and PD-L1 in melanoma: Options for new clinical opportunities
Presenter: Jorge Bartolome
Session: Poster session 13
1172P - Analysis of the microbiome of metastatic melanoma patients with complete response to immunotherapy
Presenter: Marin Golcic
Session: Poster session 13
1173P - NRAS mutation as an independent prognostic factor for resectable Chinese acral melanoma
Presenter: Yu Xu
Session: Poster session 13
1174P - Sex differences in advanced melanoma in Spain: Results from the prospective real-world study GEM 1801
Presenter: Eva Muñoz Couselo
Session: Poster session 13
1175P - Return to work after neoadjuvant versus adjuvant immunotherapy in stage III melanoma patients
Presenter: Judith Lijnsvelt
Session: Poster session 13
1176P - Planned drug holidays during immunotherapy in advanced and metastatic melanoma patients: A nation-wide study
Presenter: Anna Czarnecka
Session: Poster session 13
1177P - Assessment of tumour burden reduction per photography vs magnetic resonance imaging in patients with locally advanced basal cell carcinoma receiving sonidegib 200 mg
Presenter: Ralf Gutzmer
Session: Poster session 13
1178P - Melanoma incidence rises for pediatrics: 15-year nationwide retrospective cohort study in Korea (2004-2019)
Presenter: Jisu Oh
Session: Poster session 13
1179P - The underestimated skin cancer risk after liver transplantation: A meta-analysis of 147154 patients
Presenter: Amr Ehab El-Qushayri
Session: Poster session 13